Proteolytic modification of the extracellular matrix is essential for tissue remodeling, but also for the progression of a number of diseases, including head and neck cancer. The overall aim of this project is to understand the biochemistry, biology, and pathology of selected matrix remodeling serine proteases. We are particularly interested in the plasminogen activation (PA) system, a complex system of serine proteases, protease inhibitors, and protease receptors, whose primary function is to govern the conversion of the abundant plasma protease zymogen, plasminogen (Plg), to the active, multifunctional protease, plasmin. Plasmin acts directly or indirectly, via activation of latent pro-collagenases, to degrade components of the extracellular matrix during cell migration and tissue remodeling in development, homeostasis, tissue repair, and reproduction. In addition to degrading extracellular matrix glycoproteins, the plasminogen activation system also takes part in several other physiological processes, such as cytokine processing, signal transduction, leukocyte activation, chemotaxis, and angiogenesis inhibition. Beside its pleiotropic functions in physiological tissue remodeling, the plasminogen activation system has been implicated in the pathogenesis of a remarkable array of important human degenerative diseases, most notably tumor dissemination, atherosclerosis, rheumatoid arthritis, and ischemic brain damage. The plasminogen activation system also plays a critical role in bacterial infection, and a variety of bacterial pathogens are equipped with their own plasminogen activators, or display high affinity cell-surface receptors for plasmin. The Proteases and Tissue Remodeling Unit (PTRU) was established in July 1999 as a new laboratory in the Oral and Pharyngeal Cancer Branch. A major part of the research of the PTRU is focused on understanding the biochemistry, biology, and pathology of the plasminogen activation system. Areas of particular interest to the PTRU include the identification of the target substrates for plasmin during physiological and pathological tissue remodeling,, the identification of physiological initiators of the plasminogen activation cascade, and the function of the plasminogen activator receptor. We are also initiating a program to identify genes that are induced during incisional skin wound healing and squamous cell carcinoma. The overall long-term purpose of this project is to identify and characterize novel proteases that serve critical functions in physiological and pathological degradation of the extracellular matrix during tissue remodeling. The studies of the PTRU are carried out in collaboration with a number of researchers within the intramural and extramural communities, both nationally and internationally.

Agency
National Institute of Health (NIH)
Institute
National Institute of Dental & Craniofacial Research (NIDCR)
Type
Intramural Research (Z01)
Project #
1Z01DE000699-02
Application #
6535285
Study Section
(OPCB)
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Dental & Craniofacial Research
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Szabo, Roman; Kosa, Peter; List, Karin et al. (2009) Loss of matriptase suppression underlies spint1 mutation-associated ichthyosis and postnatal lethality. Am J Pathol 174:2015-22
Szabo, Roman; Hobson, John P; Christoph, Kristina et al. (2009) Regulation of cell surface protease matriptase by HAI2 is essential for placental development, neural tube closure and embryonic survival in mice. Development 136:2653-63
Chaipan, Chawaree; Kobasa, Darwyn; Bertram, Stephanie et al. (2009) Proteolytic activation of the 1918 influenza virus hemagglutinin. J Virol 83:3200-11
Alfano, Randall W; Leppla, Stephen H; Liu, Shihui et al. (2008) Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells. Mol Cancer Ther 7:1218-26
Alfano, Randall W; Leppla, Stephen H; Liu, Shihui et al. (2008) Potent inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin: implications for broad anti-tumor efficacy. Cell Cycle 7:745-9
Szabo, Roman; Bugge, Thomas H (2008) Type II transmembrane serine proteases in development and disease. Int J Biochem Cell Biol 40:1297-316
Liu, Shihui; Wang, Hailun; Currie, Brooke M et al. (2008) Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature. J Biol Chem 283:529-40
Madsen, Daniel H; Engelholm, Lars H; Ingvarsen, Signe et al. (2007) Extracellular collagenases and the endocytic receptor, urokinase plasminogen activator receptor-associated protein/Endo180, cooperate in fibroblast-mediated collagen degradation. J Biol Chem 282:27037-45
Bugge, Thomas H; List, Karin; Szabo, Roman (2007) Matriptase-dependent cell surface proteolysis in epithelial development and pathogenesis. Front Biosci 12:5060-70
Su, Yunpeng; Ortiz, Janelle; Liu, Shihui et al. (2007) Systematic urokinase-activated anthrax toxin therapy produces regressions of subcutaneous human non-small cell lung tumor in athymic nude mice. Cancer Res 67:3329-36

Showing the most recent 10 out of 56 publications